NR4A1 and breast cancer: A report examining predictive factors of eribulin efficacy in breast cancer showed that eribulin tended to be more effective in patients with HER2-negative, hormone receptor-negative, and triple-negative breast cancers in a pooled analysis of two phase III trials10,11.